Next Article in Journal
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2011, 4(1), 169-186; doi:10.3390/ph4010169
Review

Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata

,
 and *
Received: 14 December 2010; in revised form: 22 December 2010 / Accepted: 5 January 2011 / Published: 11 January 2011
(This article belongs to the Special Issue Anti-Infective Agents)
View Full-Text   |   Download PDF [194 KB, uploaded 11 January 2011]
Abstract: Candida glabrata is a major opportunistic human fungal pathogen causing superficial as well as systemic infections in immunocompromised individuals and several other patient cohorts. C. glabrata represents the second most prevalent cause of candidemia and a better understanding of its virulence and drug resistance mechanisms is thus of high medical relevance. In contrast to the diploid dimorphic pathogen C. albicans, whose ability to undergo filamentation is considered a major virulence trait, C. glabrata has a haploid genome and lacks the ability to switch to filamentous growth. A major impediment for the clinical therapy of C. glabrata infections is its high intrinsic resistance to several antifungal drugs, especially azoles. Further, the development of antifungal resistance, particularly during prolonged and prophylactic therapies is diminishing efficacies of therapeutic interventions. In addition, C. glabrata harbors a large repertoire of adhesins involved in the adherence to host epithelia. Interestingly, genome plasticity, phenotypic switching or the remarkable ability to persist and survive inside host immune cells further contribute to the pathogenicity of C. glabrata. In this comprehensive review, we want to emphasize and discuss the mechanisms underlying virulence and drug resistance of C. glabrata, and discuss its ability to escape from the host immune surveillance or persist inside host cells.
Keywords: Candida glabrata; fungal pathogenesis; virulence; drug resistance Candida glabrata; fungal pathogenesis; virulence; drug resistance
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Tscherner, M.; Schwarzmüller, T.; Kuchler, K. Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata. Pharmaceuticals 2011, 4, 169-186.

AMA Style

Tscherner M, Schwarzmüller T, Kuchler K. Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata. Pharmaceuticals. 2011; 4(1):169-186.

Chicago/Turabian Style

Tscherner, Michael; Schwarzmüller, Tobias; Kuchler, Karl. 2011. "Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata." Pharmaceuticals 4, no. 1: 169-186.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert